| Literature DB >> 34490899 |
Jaehyuk Kim1,2, Seung Hee Han1, Hyoung-Il Kim1,3,4.
Abstract
BACKGROUND: Previous studies evaluating the prognostic value of computed tomography (CT)-derived body composition data have included few patients. Thus, we assessed the prevalence and prognostic value of sarcopenic obesity in a large population of gastric cancer patients using preoperative CT, as nutritional status is a predictor of long-term survival after gastric cancer surgery.Entities:
Keywords: body mass index; gastric cancer; machine learning; nutrition process; sarcopenic obesity; survival
Mesh:
Year: 2021 PMID: 34490899 PMCID: PMC9290491 DOI: 10.1002/jso.26668
Source DB: PubMed Journal: J Surg Oncol ISSN: 0022-4790 Impact factor: 2.885
Figure 1Machine learning algorithm for body composition analysis. (A) Maximum intensity projection (MIP) method for L3 annotation. (B) Machine learning network: layers of the network were based on DeepLab V3+, and Resnet‐18 was used as the base network. CT, computed tomography
Figure 2Representative computed tomography images of groups based on sarcopenia and obesity criteria. Red color stands for the skeletal muscle area, yellow color stands for the visceral fat area
Figure 3Segmentation and patient groups. (A) Sarcopenia according to skeletal mass index (SMI). (B) Obesity according to visceral fat area (VFA). (C) Scatter plots of VFA and SMI. (D) Distribution of body mass index according to patient group
Baseline patient and tumor characteristics
| Control group ( | Sarcopenic group ( | Obese group ( | Sarcopenic obese group ( |
| |
|---|---|---|---|---|---|
|
| 56.1 (12.6) | 61.9 (12) | 61.7 (10.3) | 66.9 (10) | <0.001 |
|
| <0.001 | ||||
| Male | 93 (39.6%) | 62 (87.3%) | 323 (66.5%) | 48 (100%) | |
| Female | 142 (60.4%) | 9 (12.7%) | 163 (33.5%) | 0 (0%) | |
|
| <0.001 | ||||
| I/II | 202 (86.0%) | 46 (64.8%) | 349 (71.8%) | 32 (66.7%) | |
| III/IV | 33 (14.0%) | 25 (35.2%) | 137 (28.2%) | 16 (33.3%) | |
|
| 21.4 (2.3) | 20.9 (3.4) | 25 (2.9) | 22.9 (2.1) | <0.001 |
|
| 53.2 (5.7) | 52.3 (5.7) | 54.4 (5.9) | 53.5 (6.5) | 0.006 |
|
| 3607 (1636) | 4151 (1930) | 3996 (2171) | 4005 (992) | 0.054 |
|
| 0.099 | ||||
|
| 192 (81.7%) | 51 (71.8%) | 403 (82.9%) | 36 (75%) | |
|
| 43 (18.3%) | 20 (28.2%) | 83 (17.1%) | 12 (25.0%) | |
|
| 0.139 | ||||
| R0 | 225 (95.7%) | 67 (94.4%) | 477 (98.1%) | 47 (97.1%) | |
| R1–2 | 10 (4.3%) | 4 (5.6%) | 9 (1.9%) | 1 (2.1%) | |
|
| 0.087 | ||||
| I | 162 (68.9%) | 45 (63.4%) | 362 (74.5%) | 27 (56.3%) | |
| II | 34 (14.5%) | 9 (12.7%) | 49 (10.1%) | 8 (16.7%) | |
| III | 34 (14.5%) | 14 (19.7%) | 71 (14.6%) | 13 (27.1%) | |
| IV | 5 (2.1%) | 3 (4.2%) | 4 (0.8%) | 0 (0%) | |
|
| 117.9 (52.4) | 64 (37.8) | 183.3 (85.0) | 117.4 (34.7) | <0.001 |
|
| 63.2 (25.1) | 52.7 (29.3) | 192.3 (77.6) | 156.7 (38.9) | <0.001 |
|
| 132.6 (38.1) | 107.6 (30.8) | 174.3 (59.4) | 125.4 (12.2) | <0.001 |
|
| 46.6 (22.0) | 23.7 (15.1) | 70 (35.7) | 42 (12.5) | <0.001 |
|
| 24.7 (10.0) | 19.3 (10.9) | 71.9 (28.3) | 56.2 (14.8) | <0.001 |
|
| 51.2 (12.8) | 38.8 (10.4) | 64.5 (20.0) | 44.8 (3.9) | <0.001 |
Note: Data are presented as the mean (standard deviation) or number (percentage).
Abbreviations: ASA, American Society of Anesthesiologists; TNM, tumor, nodes, and metastasis.
Analysis of variance for continuous variables; chi‐square test for categorical data.
R0 = curative resection, R1 = microscopic residual cancer, R2 = macroscopic residual cancer.
Figure 4Overall survival according to the sarcopenia, obesity, and sarcopenic obesity groups. (A) Sarcopenia versus non‐sarcopenia: all patients (p = 0.018). (B) Sarcopenia versus non‐sarcopenia: patients with stage I/II disease (p = 0.030). (C) Sarcopenia versus non‐sarcopenia: patients with stage III/IV disease (p = 0.945). (D) Obesity versus non‐obesity: all patients (p = 0.293). (E) Obesity versus non‐obesity: patients with stage I/II disease (p = 0.046). (F) Obesity versus non‐obesity: patients with stage III/IV disease (p = 0.825). (G) Sarcopenic obesity versus non‐sarcopenic obesity: all patients (p < 0.001). (H) Sarcopenic obesity versus non‐sarcopenic obesity: patients with stage I/II disease (p < 0.001). (I) Sarcopenic obesity versus non‐sarcopenic obesity: patients with stage III/IV disease (p = 0.392)
Univariate and multivariate analyses of variables associated with overall survival
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Coefficient ( | Hazard ratio (95% CI) | Coefficient ( | Hazard ratio (95% CI) | |
| Age | 0.039 (0.012) | 1.040 (1.016–1.064) | ||
| Sex | −0.579 (0.274) | 0.561 (0.327–0.960) | ||
| ASA physical status class (III/IV vs. I/II) | 0.687 (0.254) | 1.988 (1.208–3.272) | ||
| Body mass index | −0.037 (0.039) | 0.964 (0.893–1.041) | ||
| Prognostic nutritional index | −0.110 (0.017) | 0.896 (0.866–0.927) | −0.067 (0.019) | 0.935 (0.901–0.970) |
| Neutrophil count | 0.145 (0.035) | 1.156 (1.079–1.239) | 0.096 (0.034) | 1.100 (1.030–1.175) |
| Extent of gastrectomy (total vs. subtotal) | 1.213 (0.247) | 2.519 (1.776–3.575) | 0.669 (0.254) | 1.952 (1.186–3.212) |
| Resection (R1/2 vs. R0) | 2.606 (0.314) | 13.542 (7.320–25.054) | 1.560 (0.329) | 4.758 (2.496–9.070) |
| Depth of invasion (T3/4 vs. T1/2) | 2.177 (0.266) | 8.821 (5.242–14.845) | ||
| Lymph node metastasis (+ vs. −) | 2.334 (0.286) | 10.318 (5.896–18.056) | 1.826 (0.303) | 6.212 (3.433–11.241) |
| Sarcopenic obesity (SO vs. non‐SO) | 1.201 (0.343) | 3.325 (1.698–6.508) | 0.973 (0.35) | 2.645 (1.333–5.249) |
Abbreviations: ASA, American Society of Anesthesiologists; CI, confidence interval; non‐SO, non‐sarcopenic obesity counter group; SE, standard error; SO, sarcopenic obesity group.